Pfizer Inc. (PFE)
| Market Cap | 138.15B |
| Revenue (ttm) | 62.46B |
| Net Income (ttm) | 7.88B |
| Shares Out | 5.69B |
| EPS (ttm) | 1.38 |
| PE Ratio | 17.57 |
| Forward PE | 8.63 |
| Dividend | $1.72 (7.08%) |
| Ex-Dividend Date | May 9, 2025 |
| Volume | 40,345,296 |
| Open | 23.97 |
| Previous Close | 23.97 |
| Day's Range | 23.96 - 24.42 |
| 52-Week Range | 20.92 - 31.54 |
| Beta | 0.49 |
| Analysts | Hold |
| Price Target | 29.92 (+23.13%) |
| Earnings Date | Jul 29, 2025 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for PFE stock is "Hold." The 12-month stock price forecast is $29.92, which is an increase of 23.13% from the latest price.
News
5 Ideal 'Safe' Buys From June Fortune Return On Leadership Screen
Coincident to the June 5, 2025 annual launch of their Fortune 500, Fortune also partnered with Indiggo to measure Return On Leadership, called the ROL100. Arnold research focused on those 100 using YC...
RFK Jr.'s firing of CDC vaccine advisors 'circumvents science' and could threaten public health, experts say
Health and Human Services Secretary Robert F. Kennedy Jr. has gutted a key government panel of vaccine advisors, a stunning move that some public health experts say undermines science, disrupts a trus...
Vaccine actions and policy positions under US Health Secretary Kennedy
U.S. Health Secretary Robert F. Kennedy Jr., a long-time vaccine skeptic, has been making sweeping changes to reshape U.S. regulation of vaccines, food and medicine.
Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up
Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S. Health Secretary Robert F. Kennedy Jr. fired all members of an expert vaccin...
Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.
Investors will be waiting for news on how the makeup of a reconstituted ACIP will look like.
Pfizer: Dividend Investor's Dream And Patent Cliff Nightmare
Pfizer offers a high 7.4% dividend yield and trades at low valuation multiples, making it attractive for income-focused investors despite recent underperformance. The company faces significant patent ...
Pfizer Inc. (PFE) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Pfizer Inc. (NYSE:PFE) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 8:00 AM ET Company Participants Albert Bourla - Chairman of the Board & CEO Conference Call Participants Asa...
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Pfizer CEO says 'no commitments' made in meetings with US governments on drug pricing
Pfizer and other drug companies have met with the Trump administration to discuss most-favored-nation pricing but no commitments have been made, Chief Executive Albert Bourla said on Monday at an indu...
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 10% (June 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter...
Buy 7 Ideal 'Safer' May Dividends, Out Of 40 Reader Tags
My yield-based 'dogcatcher' strategy spotlights high-yield stocks whose dividends from $1,000 invested exceed their share price, favoring underdogs for income growth. Analyst targets project average n...
These Stocks Are The High-Yield Dividend Investor's Best Friend
High-yield stocks are often riddled with flaws. However, there are some high-yield stocks available today that check all of my boxes. I share some of my top high-yield picks of the moment.
Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.
Pfizer's R&D Optimization Delivers Great Results & Secure Dividends
PFE's meltdown has already triggered the richer forward dividend yields, made secure by the growing cash flow and the ongoing cost optimizations. The same has been observed in the FQ1'25 adj EPS outpe...
Buy, Sell, Or Hold PFE Stock At $23?
Pfizer (NYSE:PFE) stock is down around 25% from its 52-week high of over $31 to $23 now. Pipeline setbacks, including an experimental treatment for Duchenne muscular dystrophy (DMD) failing in a late-...
June's Top 10 High-Yield Stocks: Build A Path To A 10%+ Yield By 2035
My top 10 high-yield picks for June 2025 balance attractive dividend yields, strong financials, and competitive advantages to reduce risk and enhance returns. I use a rigorous four-step selection proc...
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Gold...
Pfizer (PFE) CEO on Braftovi Reducing Colorectal Cancer Death Risk "in Half"
Dr. Albert Bourla, CEO of Pfizer (PFE), joins Nicole Petallides on Morning Trade Live to discuss the latest results of his company's Braftovi drug trials. According to Dr. Bourla, results showed it ca...
Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression
An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to AstraZeneca's Faslodex in patients with a specific gene mutation, according t...
Carat Group's Fred Hassan dives into what pharma companies to watch at 2025 ASCO Annual Meeting
Fred Hassan, Carat Group chairman, joins 'Money Movers' to discuss pharma innovation in 2025 and what companies he's watching in the sector.
Pfizer's BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafe...
Collaborations for Change: AUA and Pfizer Select Recipients for $1.5 Million Grant Program to Improve Advanced Prostate Cancer Care
BALTIMORE, May 29, 2025 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) is excited to announce it has selected seven grant winners to split $1.5 million as part of a collaborative initia...
Hearing Against Pfizer Set For 30 May In Contraceptive ‘Depo-Provera' Multidistrict Litigation Overseen By Levin Papantonio
PENSACOLA, Fla.--(BUSINESS WIRE)--A Case Management Conference (CMC) in the Depo-Provera legal action against Pfizer Inc. (NYSE:PFE) will take place on Friday, 30 May at 9:00am CT in the United States...
Unlocking Pfizer's Value: Cost Controls And Oncology Pipeline
Despite recent underperformance, a "Buy" rating on Pfizer is reiterated due to a strong Q1 EPS beat, driven by significant cost controls and margin improvement, signaling operational strength. Managem...
Investing In The Promising PD1/VEGF Bispecific - Pfizer And Instil Could Be Good Candidates
Bispecific antibodies targeting PD1 and VEGF show promise in treating non-small cell lung cancer, with Summit Therapeutics' Ivonescimab outperforming Pembrolizumab in a Phase III trial. While immature...